Literature DB >> 23394762

CT-guided thin needles percutaneous cryoablation (PCA) in patients with primary and secondary lung tumors: a preliminary experience.

Claudio Pusceddu1, Barbara Sotgia, Rosa Maria Fele, Luca Melis.   

Abstract

PURPOSE: To report the data of our initial experience with CT-guided thin cryoprobes for percutaneous cryoablation (PCA) in patients with primary and secondary pulmonary tumors.
MATERIAL AND METHODS: CT-guided thin needles PCA was performed on 34 lung masses (11 NSCLC=32%; 23 secondary lung malignancies=68%) in 32 consecutive patients (24 men and 8 women; mean age 67 ± 10 years) not suitable for surgical resection. Lung masses were treated using two types of cryoprobes: IceRod and IceSeed able to obtain different size of iceball. The number of probes used ranged from 1 to 5 depending on the size of the tumor. After insertion of the cryoprobes into the lesion, the PCA were performed with two 2 (91%) or 3 (9%) cycles each of 12 min of freezing followed by a 4 min active thawing phase and a 4 min passive thawing phase for each one for all treatments.
RESULTS: All cryoablation sessions were successfully completed. All primary and metastatic lung tumors were ablated. No procedure-related deaths occurred. Morbidity consisted of 21% (7 of 34) pneumothorax and 3% (1 of 34) cases asymptomatic small pulmonary hemorrhage, respectively, all of CTCAE grade 1 (Common Terminology Criteria for Adverse Events). Low density of entire lesion, central necrosis and solid mass appearance were identify in 21 (62%), 7 (21%) and 6 (17%) of cryoablated tumors, respectively. No lymphadenopathy developed in the region of treated lesions. Technical success (complete lack of enhancement) was achieved in 82%, 97% and 91% of treated lesions at 1-, 3- and 6-months CT follow-up scan, respectively (p<.000). Comparing the tumor longest diameter between the baseline and at 6 month CT images, technical success was revealed in 92% cases (p<.000).
CONCLUSION: Our preliminary experience suggests that PCA is a feasible treatment option. Well-designed clinical trials with a larger patient population are necessary to further investigate the long-term results and prognostic factors.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23394762     DOI: 10.1016/j.ejrad.2012.12.010

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  10 in total

1.  Catastrophic complications following cryoablation of lung cancer.

Authors:  Vrinda Vyas; Manju Paul
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-10-16

2.  CT-guided percutaneous cryoablation of central lung tumors.

Authors:  Errol Colak; Servet Tatlı; Paul B Shyn; Kemal Tuncalı; Stuart G Silverman
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

3.  Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non-small cell lung cancer.

Authors:  Sushant Kumar Das; Ya-Yong Huang; Bing Li; Xiao Xuan Yu; Ru Hui Xiao; Han Feng Yang
Journal:  Oncol Lett       Date:  2019-11-25       Impact factor: 2.967

4.  Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis.

Authors:  Binghu Jiang; Morgan A Mcclure; Tianming Chen; Shilin Chen
Journal:  Ann Thorac Med       Date:  2018 Oct-Dec       Impact factor: 2.219

5.  Initial experience with transbronchial cryoablation as a novel local treatment for malignant peripheral lung lesions.

Authors:  Mitsutomo Kohno; Ryo Hashimoto; Kana Oiwa; Hideki Yashiro; Seishi Nakatsuka; Masafumi Kawamura; Masayuki Iwazaki
Journal:  BMJ Open Respir Res       Date:  2018-12-15

6.  Co-ablation versus cryoablation for the treatment of stage III-IV non-small cell lung cancer: A prospective, noninferiority, randomized, controlled trial (RCT).

Authors:  Wuwei Yang; Yonghui An; Quanwang Li; Chuanbo Liu; Baorang Zhu; Qianfu Huang; Mengfei Zhao; Fei Yang; Huasong Feng; Kaiwen Hu
Journal:  Thorac Cancer       Date:  2020-12-14       Impact factor: 3.500

7.  Microwave ablation vs. cryoablation for treatment of primary and metastatic pulmonary malignant tumors.

Authors:  Hong-Wei Li; Yong-Jun Long; Gao-Wu Yan; Anup Bhetuwal; Li-Hua Zhuo; Hong-Chao Yao; Jie Zhang; Xing-Xiong Zou; Pei-Xi Hu; Han-Feng Yang; Yong Du
Journal:  Mol Clin Oncol       Date:  2022-01-14

8.  Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE).

Authors:  Matthew R Callstrom; David A Woodrum; Francis C Nichols; Jean Palussiere; Xavier Buy; Robert D Suh; Fereidoun G Abtin; Bradley B Pua; David C Madoff; Sandeep L Bagla; Dimitrios C Papadouris; Hiran C Fernando; Damian E Dupuy; Terrance T Healey; William H Moore; Thomas V Bilfinger; Stephen B Solomon; Hooman Yarmohammadi; Henry J Krebs; Charles J Fulp; Antoine Hakime; Lambros Tselikas; Thierry de Baere
Journal:  J Thorac Oncol       Date:  2020-03-07       Impact factor: 20.121

Review 9.  Cryoablation of early-stage primary lung cancer.

Authors:  Masanori Inoue; Seishi Nakatsuka; Masahiro Jinzaki
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

10.  Characteristic CT Findings After Percutaneous Cryoablation Treatment of Malignant Lung Nodules.

Authors:  Ammar Chaudhry; Vadim Grechushkin; Mahsa Hoshmand; Choo Won Kim; Andres Pena; Brett Huston; Yair Chaya; Thomas Bilfinger; William Moore
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.